These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 1418372)

  • 1. Immunotoxins: the power and the glory.
    Wawrzynczak EJ; Derbyshire EJ
    Immunol Today; 1992 Oct; 13(10):381-3. PubMed ID: 1418372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant immunotoxins for treating cancer.
    FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
    Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application considered for immunotoxin in treatment of graft-vs-host disease.
    Skolnick A
    JAMA; 1991 Apr; 265(16):2041-2. PubMed ID: 2013915
    [No Abstract]   [Full Text] [Related]  

  • 4. Rationale for clinical use of immunotoxins in cancer and autoimmune disease.
    Byers VS; Baldwin RW
    Semin Cell Biol; 1991 Feb; 2(1):59-70. PubMed ID: 1954344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotoxins for the therapy of graft versus host disease.
    Salzman D; LeMaistre F
    Cancer Treat Res; 1993; 68():133-44. PubMed ID: 8105848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
    Zovickian J; Johnson VG; Youle RJ
    J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Basic concept and clinical application of monoclonal antibody].
    Nihon Rinsho; 1990 Aug; 48 Suppl():938-1124. PubMed ID: 2232229
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic use of immunotoxins.
    Cobb PW; LeMaistre CF
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):6-13. PubMed ID: 1509295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
    Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New developments in therapy of non-Hodgkin lymphomas with monoclonal antibodies].
    Buske C; Feuring-Buske M; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 1999 Jul; 124(27):842-7. PubMed ID: 10432945
    [No Abstract]   [Full Text] [Related]  

  • 11. [Selective cytotoxicity of antibody-ricin-A-chain conjugate for human tumor B cells. II. Comparison of activity of immunotoxins conjugated with poly- and monoclonal antibodies].
    Tonevitskiĭ AG; Zhukova OS; Rakhmanova VA; Arsen'eva EL; Bogacheva GT
    Mol Biol (Mosk); 1988; 22(4):911-6. PubMed ID: 3141780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotoxins in cancer therapy: Review and update.
    Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
    Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies. Targeted treatment.
    Mayo Clin Health Lett; 2003 Mar; 21(3):1-3. PubMed ID: 12703461
    [No Abstract]   [Full Text] [Related]  

  • 14. Rational design of immunotoxins: current progress and future prospects.
    Wawrzynczak EJ
    Anticancer Drug Des; 1992 Oct; 7(5):427-41. PubMed ID: 1388633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
    Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
    Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant toxins for the treatment of cancer.
    Kreitman RJ
    Curr Opin Mol Ther; 2003 Feb; 5(1):44-51. PubMed ID: 12669470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody drug conjugates - Trojan horses in the war on cancer.
    Iyer U; Kadambi VJ
    J Pharmacol Toxicol Methods; 2011; 64(3):207-12. PubMed ID: 21843648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM
    Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.
    Grossbard ML; Lambert JM; Goldmacher VS; Spector NL; Kinsella J; Eliseo L; Coral F; Taylor JA; Blättler WA; Epstein CL
    J Clin Oncol; 1993 Apr; 11(4):726-37. PubMed ID: 7683045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of steroid-resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin.
    Kernan NA; Byers V; Scannon PJ; Mischak RP; Brochstein J; Flomenberg N; Dupont B; O'Reilly RJ
    JAMA; 1988 Jun; 259(21):3154-7. PubMed ID: 3285046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.